What specific assets did Evonik sell, to whom, and when was the transaction completed?

Evonik sold part of its active pharmaceutical ingredient (API) production assets located in Hanau, Germany, to the contract manufacturing organization ProChem Group; the transaction was completed on June 19, 2026.

Why did Evonik divest these assets, and how does this align with its broader pharmaceutical health strategy?

Evonik divested the assets to support the continued growth of its Pharma Health business line by optimizing its asset portfolio and refocusing investment and growth efforts on core technological expertise—specifically complex oral and injectable delivery technologies and precision biologics solutions.

Evonik Sells German API Production Assets

Jun 29, 2026

Evonik completed the sale of its Hanau, Germany API production assets to ProChem Group to optimize its asset portfolio. The move supports Evonik's strategy to concentrate investments on complex delivery systems and bio solutions.

ccin

2026-06-29

Evonik Sells German API Production Assets

2026-07-28

Insight: Bullish Signals as Q2 Results Season Kicks into Gear, But Inflation Remains a Hurdle

Evonik Sells German API Production Assets

FAQ